Multi Disciplinary Sickle Cell Disease Obstetrics Care Program in Ghana (NCT07488091) | Clinical Trial Compass
RecruitingNot Applicable
Multi Disciplinary Sickle Cell Disease Obstetrics Care Program in Ghana
Ghana198 participantsStarted 2026-01-22
Plain-language summary
The goal of this observational study is to determine the feasibility and effectiveness of initiating a multidisciplinary sickle cell disease (SCD) obstetrics program for women with SCD in a non-academic hospital.
The main question it aims to answer is: In a before-and-after study design, we will test the hypothesis that multidisciplinary care for pregnant women with SCD in a non-academic hospital will result in a 50% relative risk reduction in mortality compared to the mortality rate in pregnant women with SCD in the same hospital before the multidisciplinary care.
Participants will be managed using the academic hospital's multidisciplinary sickle cell disease obstetrics protocol adapted for the non-academic hospital
Who can participate
Age range
18 Years – 45 Years
Sex
FEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
* Pregnant women with a confirmed laboratory diagnosis of sickle cell disease
* Pregnancy confirmed by a pelvic ultrasound scan
* Pregnancy should be 34 weeks' gestation or less
* Pregnant women should be aged 18 - 45 years
* Pregnant women should be attendants at the non-academic hospital
Exclusion criteria
* All pregnant women with sickle cell disease who do not provide informed consent
* All pregnant women with sickle cell disease who are referred for management of acute complications and hospital admission
* All pregnant women with sickle cell disease who are referred for labor and delivery
* All pregnant women with SCD who plan on delivering outside the non-academic hospital and won't be able to adhere to the follow-up procedures during the puerperium (the first six weeks after childbirth)
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Maternal mortality
Timeframe: Up to 40 weeks for each participant
Trial details
NCT IDNCT07488091
SponsorUniversity of Ghana Medical School
Sponsor typeOTHER
Study typeINTERVENTIONAL
Primary completion2028-01-15
Contact for this trial
Dr. Eugenia Vicky N. K. Asare, Senior Specialist Hematologist, MBChB